Doxorubicin Market Report 2025

The doxorubicin market size has grown strongly in recent years. It will grow from $1.33 billion in 2024 to $1.42 billion in 2025 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to chemotherapy advancements, oncology treatment standard, clinical efficacy, patient survival rates, physician recommendations.

The doxorubicin market size is expected to see strong growth in the next few years. It will grow to $1.87 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to personalized medicine advancements, targeted drug delivery systems, immunotherapy combinations, genomic and biomarker research, precision oncology growth. Major trends in the forecast period include nanotechnology integration, combination therapies, biosimilar market expansion, adjuvant therapy focus, cardioprotective interventions.

The rising prevalence of cancer is propelling the doxorubicin market. Cancer encompasses a range of diseases characterized by the abnormal and uncontrolled growth of cells. Doxorubicin is a widely used antibiotic in chemotherapy that helps combat various cancers by damaging the DNA of cancer cells, thereby inhibiting their growth. The increasing incidence of cancer has led to a greater demand for doxorubicin. For example, the World Health Organization reported that in 2022, there were approximately 20 million new cancer cases and 9.7 million deaths worldwide. About 53.5 million people were living five years post-diagnosis, and roughly 1 in 5 individuals will develop cancer in their lifetime, with around 1 in 9 men and 1 in 12 women dying from the disease. Consequently, the growing number of cancer patients is driving the demand for doxorubicin.

The increase in genetic disorders is expected to drive the growth of the doxorubicin market in the future. Newborn screening is a physical examination conducted shortly after birth to check for specific health conditions, enabling healthcare professionals to identify and address particular needs before they cause illness. This screening can help identify infants at high risk for developing breast and ovarian cancer, allowing for early preventive measures using doxorubicin. For example, in 2022, the Texas Department of State Health Services reported that approximately 394,000 babies were screened, with 1,130 found to be affected by one of the newborn screening disorders. Therefore, the rise in genetic disorders is contributing to the growth of the doxorubicin market.

Major companies in the doxorubicin market are focused on developing innovative products, including chemotherapy medications, to improve treatment efficacy and minimize side effects for cancer patients. Chemotherapy drugs work by targeting and killing rapidly dividing cancer cells, but they can also affect some healthy cells, resulting in side effects. Recent advancements aim to enhance specificity and reduce these adverse effects. For example, in August 2024, Lupin Limited, an India-based pharmaceutical company, launched Doxorubicin Hydrochloride Liposome Injection. This injection is used to treat advanced ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. Its liposomal formulation enables targeted delivery, which helps reduce systemic side effects and improve patient tolerance. This approach enhances treatment efficacy, making it a vital option in oncology therapies.

Major players in the doxorubicin market are strategically focusing on innovative drug development to enhance their market standing. Notably, in May 2023, Dr. Reddy's Laboratories, an India-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for the launch of Doxorubicin Hydrochloride Liposome Injection in the US market. This treatment targets ovarian and breast cancer, providing patients with a new therapeutic option. The approval process involved pre-clinical studies, clinical trials, and the submission of a New Drug Application (NDA) to the FDA to demonstrate the drug's safety and efficacy.

In March 2024, Johnson & Johnson, a US-based company engaged in the research, development, manufacturing, and sale of a diverse range of pharmaceutical products and medical devices, acquired Ambrx Biopharma, Inc. for $2 billion. This acquisition enhances Johnson & Johnson's capabilities in developing next-generation antibody-drug conjugates (ADCs), with a particular emphasis on targeting prostate cancer, an area of significant interest for the company. Ambrx Biopharma specializes in creating advanced ADCs for various cancer indications.

Major companies operating in the doxorubicin market include Pfizer Inc., Johnson and Johnson, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals, Mylan Pharmaceuticals Inc., Accord Healthcare Ltd., TTY Biopharm Company Limited, Cadila Pharmaceuticals, Neon Laboratories Limited, APP Pharmaceuticals Manufacturing LLC, Sun Pharmaceutical Industries Ltd., Transo-Pharm Handels GmbH, LGM Pharma, Zhejiang Hisun Pharma, Actavis Pharma, Celon Laboratories Limited, Samarth Life Sciences Pvt. Ltd.

North America was the largest region in the doxorubicin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the doxorubicin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the doxorubicin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Doxorubicin is an anthracycline antibiotic used in cancer therapy due to its strong antitumor effects. It treats various cancers, including breast cancer, lung cancer, and hematological malignancies. The drug works by inhibiting DNA replication, which prevents cancer cells from dividing and growing.

Doxorubicin is available in two main forms lyophilized powder and doxorubicin injection. Lyophilized doxorubicin powder denotes a freeze-dried version of the chemotherapy drug, where the water content has been removed. Lyophilization is utilized to enhance preservation, ensuring the drug's stability and longevity. These formulations find application in the treatment of breast cancer, kidney cancer, liver cancer, sarcoma, ovarian cancer, lung cancer, leukemia, multiple myeloma, among others, and are accessible through hospital pharmacies, retail pharmacies, and online pharmacies.

The doxorubicin market research report is one of a series of new reports that provides doxorubicin market statistics, including the doxorubicin industry's global market size, regional shares, competitors with a doxorubicin market share, detailed doxorubicin market segments, market trends, and opportunities, and any further data you may need to thrive in the doxorubicin industry. This doxorubicin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The doxorubicin market consists of sales of doxorubicin hydrochloride injections, adriamycin, doxil, myocet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.